Octreotide LAR (Long-acting release)

DRUG2 trials

Sponsors

Carmen Schade-Brittinger, HTA Co., Ltd.

Conditions

NETS Ga68 Lu177Neuroendocrine Tumors

Phase 3

Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

CompletedNCT00171873

Carmen Schade-BrittingerNeuroendocrine Tumors

Start: 2001-09-30End: 2013-12-31Updated: 2020-03-26

A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs

RecruitingNCT07057622

HTA Co., Ltd.NETS Ga68 Lu177

Start: 2023-12-12End: 2027-02-24Target: 184Updated: 2025-07-10

Related Papers

Health-related quality of life (HRQoL) for octreotide long-acting (oct l-a) vs. placebo (PBO) in patients (pts) with metastatic midgut neuroendocrine tumors (mmNETs) in the phase IIIb PROMID trial

Annals of Oncology2018-10-01